Five years of experience with rituximab plus high-dose dexamethasone for relapsed/refractory chronic lymphocytic leukemia

INTRODUCTION: High-dose methylprednisolone (HDMP) in combination with rituximab is active in the treatment of relapsed/refractory chronic lymphocytic leukemia (CLL), but serious infections are frequent. Recently published data suggested that high-dose dexamethasone might be equally effective as HDMP...

Descripción completa

Detalles Bibliográficos
Autores principales: Šimkovič, Martin, Motyčková, Monika, Belada, David, Vodárek, Pavel, Kapoor, Rahul, Jaffar, Hamna, Vrbacký, Filip, Žák, Pavel, Smolej, Lukáš
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2015
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4848354/
https://www.ncbi.nlm.nih.gov/pubmed/27186190
http://dx.doi.org/10.5114/aoms.2016.55425

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4848354/
https://www.ncbi.nlm.nih.gov/pubmed/27186190
http://dx.doi.org/10.5114/aoms.2016.55425

Ejemplares similares